Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT 3 versus NYSTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT 3 versus NYSTEX.
MONISTAT 3 vs NYSTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and lead to leakage of intracellular contents and cell death.
One vaginal suppository (200 mg miconazole nitrate) intravaginally at bedtime for 3 consecutive days; or one applicatorful (5 g) of 4% vaginal cream intravaginally at bedtime for 7 days.
Topical: Apply thin layer to affected area twice daily. Oral suspension (nystatin): 500,000-1,000,000 units (5-10 mL) four times daily for candidiasis. Vaginal tablets: 1 tablet (100,000 units) intravaginally once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 30 hours after topical vaginal application; prolonged in hepatic impairment.
Variable; estimated 2-5 hours for systemic absorption (if any), but negligible systemic levels due to poor absorption.
Primarily fecal (97%) via biliary excretion; renal excretion of unchanged drug is negligible (<1%).
Primarily fecal (>95%) as unchanged drug; minimal renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal